ImmuCell (NASDAQ:ICCC – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare ImmuCell to similar businesses based on the strength of its institutional ownership, risk, earnings, valuation, dividends, analyst recommendations and profitability.
Institutional & Insider Ownership
13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 5.7% of ImmuCell shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings for ImmuCell and its peers, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ImmuCell | 0 | 1 | 0 | 0 | 2.00 |
| ImmuCell Competitors | 7844 | 13796 | 25806 | 1039 | 2.41 |
As a group, “Pharmaceuticals” companies have a potential upside of 24.69%. Given ImmuCell’s peers stronger consensus rating and higher probable upside, analysts clearly believe ImmuCell has less favorable growth aspects than its peers.
Earnings & Valuation
This table compares ImmuCell and its peers gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| ImmuCell | $27.64 million | -$1.04 million | 134.38 |
| ImmuCell Competitors | $3.55 billion | $3.17 billion | 562.76 |
ImmuCell’s peers have higher revenue and earnings than ImmuCell. ImmuCell is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares ImmuCell and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ImmuCell | 5.66% | 6.25% | 4.15% |
| ImmuCell Competitors | -2,398.26% | -203.62% | -15.08% |
Volatility & Risk
ImmuCell has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, ImmuCell’s peers have a beta of -0.04, suggesting that their average share price is 104% less volatile than the S&P 500.
Summary
ImmuCell peers beat ImmuCell on 9 of the 13 factors compared.
ImmuCell Company Profile
ImmuCell is an animal health company focused on products for cattle. It develops, manufactures and markets products intended to support the health of dairy and beef herds. Its best-known product line, First Defense, consists of oral antibody products given to newborn calves to help protect against common causes of scours, a form of calf diarrhea. The products are designed to provide targeted antibodies during the early stages of life. ImmuCell has also developed Re-Tain, a non-antibiotic product for subclinical mastitis in dairy cows.
Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.
